All You Need to Know About Biofrontera Inc. (BFRI) Rating Upgrade to BuyZacks Investment Research • Monday
Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer AccountsAccesswire • 08/29/23
Biofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz(R)Accesswire • 08/28/23
Biofrontera Inc. Reports Second Quarter 2023 Financial Results and Provides a Business UpdateAccesswire • 08/11/23
Biofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Basal Cell CarcinomaAccesswire • 08/10/23
Biofrontera Inc. Announces Preliminary Second Quarter Revenues are Up 26% to 31%Accesswire • 07/13/23
Biofrontera Inc. Sponsors The Sun Bus, Delivering Free Mobile Skin Cancer Screenings Across the U.S.Accesswire • 06/12/23
Biofrontera Inc. Begins Development of a Portable Photodynamic Therapy Lamp for Use with Ameluz(R)-PDTAccesswire • 06/01/23
Biofrontera Inc. Names Founder and Executive Chairman Hermann Luebbert as Chief Executive OfficerAccesswire • 05/30/23
Biofrontera Inc. Announces U.S. Patent Issued for Photodynamic Therapy Protocol with Reduced Side EffectsAccesswire • 05/15/23
Biofrontera Inc. (BFRI) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/12/23
Biofrontera Inc. Reports First Quarter 2023 Financial Results and Provides a Business UpdateAccesswire • 05/12/23
Biofrontera Collaborates with The Skin Cancer Foundation to Raise Awareness of Skin Cancer PreventionAccesswire • 05/09/23
Biofrontera Inc. Announces Last Patient Out in Phase I Study to Evaluate Safety and Tolerability in Treating Actinic Keratosis Using 3 Tubes of Ameluz(R)Accesswire • 04/26/23